TP53 and colonic neoplasm: More recently, our research group demonstrated that AdoMet may overcome uL3-mediated drug resistance in p53-deleted HCT116 colon cancer cells by inducing cell cycle arrest at the S-phase, inhibition of autophagy, increase of reactive oxygen species generation, and finally activation of the apoptotic pathway [22].